Real-world observational results from a database of 48 million men in the United States: Relationship of cardiovascular disease, diabetes mellitus and depression with age and erectile dysfunction

Goldstein, Irwin; Chambers, Richard; Tang, WingYu; Stecher, Vera J.; Hassan, Tamer

doi:10.1111/ijcp.13078

Cited by 33 publications

(22 citation statements)

References 27 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This assessment was furthermore supported by the majority of men self-reporting frequent episodes of both nocturnal and morning erections. Interestingly, the assertion by Reed-Maldonado et al [6] that psychiatric comorbidities are more prevalent in men with proposed psychogenic ED holds true in the present cohort, as a prevalence of 23% is far above the national age-matched average [18]. 13 One-third of the men experienced full return of erectile function with no current need for medication.…”

Section: Discussionmentioning

confidence: 50%

A treatment algorithm for healthy young men with erectile dysfunction

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 50%

A treatment algorithm for healthy young men with erectile dysfunction

et al. 2018

View full text Add to dashboard Cite

show abstract

“…PDE5i-nonresponsive ED patients always have comorbidities, including diabetes, cardiovascular disease, and metabolic syndrome, among others [15][16]. The nerves, blood vessels, and cavernous tissues in the penis can be injured as a result of these comorbidities, which is the basis of ED development [17][18].…”

Section: Possible Causes For Ed In Pde5i Nonrespondersmentioning

confidence: 99%

Practical Approaches to Treat ED in PDE5i Nonresponders

et al. 2020

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a common sexual disorder in adult males and one of the most important factors affecting their quality of life and that of their partners. Although PDE5 inhibitors (PDE5is) are the first choice for improving erectile function, there is a substantial proportion of ED patients, termed PDE5i nonresponders, who do not respond to PDE5is. Because of the lack of effective therapies, these patients always have serious social and psychological problems due to ED, which should be addressed. Here, we review the available literature about ED and PDE5is and propose several strategies for mitigating ED in PDE5i nonresponders.

show abstract

“…Depending on the surgical procedure (retropubic, uni-or bilateral nerve sparing, laparoscopic/robotic techniques) the overall rate of ED in patients following radical prostatectomy/cystectomy has been determined to be 40-75% [46][47][48]. Among diabetics, the prevalence of ED ranges from 35% to almost 90% [49,50]. According to the Cologne Male Survey, patients with diabetes mellitus have an approximately four-fold higher risk for ED when compared to healthy males [51].…”

Section: Intra-cavernous Transurethral or Topical Administration Of mentioning

confidence: 99%

The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts

Kedia

Ückert

Tsikas

et al. 2020

JCM

View full text Add to dashboard Cite

It is widely accepted that disorders of the male (uro)genital tract, such as erectile dysfunction (ED) and benign diseases of the prostate (lower urinary tract symptomatology or benign prostatic hyperplasia), can be approached therapeutically by influencing the function of both the vascular and non-vascular smooth muscle of the penile erectile tissue or the transition zone/periurethral region of the prostate, respectively. As a result of the discovery of nitric oxide (NO) and cyclic guanosine monophosphate (GMP) as central mediators of penile smooth muscle relaxation, the use of drugs known to increase the local production of NO and/or elevate the intracellular level of the second messenger cyclic GMP have attracted broad attention in the treatment of ED of various etiologies. Specifically, the introduction of vasoactive drugs, including orally active inhibitors of the cyclic GMP-specific phosphodiesterase (PDE) 5, has offered great advantage in the pharmacotherapy of ED and other diseases of the genitourinary tract. These drugs have been proven efficacious with a fast on-set of action and an improved profile of side-effects. This review summarizes current strategies for the treatment of ED utilizing the application of vasoactive drugs via the oral, transurethral, topical, or self-injection route.

show abstract

Real-world observational results from a database of 48 million men in the United States: Relationship of cardiovascular disease, diabetes mellitus and depression with age and erectile dysfunction

Abstract: In the real-world setting, ED diagnosis was associated with CVD, DM and depression across age groups, suggesting a need for inquiry about the potential for comorbidities among these men as a preventative measure against potentially serious future events.

Cited by 33 publications

References 27 publications

A treatment algorithm for healthy young men with erectile dysfunction

A treatment algorithm for healthy young men with erectile dysfunction

Practical Approaches to Treat ED in PDE5i Nonresponders

The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts

Contact Info

Product

Resources

About